Related Experiment Video
Updated: Sep 25, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer
Zemin Hou1, Shengsong Huang2, Zejie Mei1
1State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China.
Abstract:
Prostate cancer continuously progresses following deprivation of circulating androgens originating from the testis and adrenal glands, indicating the existence of oncometabolites beyond androgens. In this study, mass-spectrometry-based screening of clinical specimens and a retrospective analysis on the clinical data of prostate cancer patients indicate the potential oncogenic effects of progesterone in patients. High doses of progesterone activate canonical and non-canonical androgen receptor (AR) target genes. Physiological levels of progesterone facilitate cell proliferation via GATA2. Inhibitors of 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) has been discovered and shown to suppress the generation of progesterone, eliminating its transient and accumulating oncogenic effects. An increase in progesterone is associated with poor clinical outcomes in patients and may be used as a predictive biomarker. Overall, we demonstrate that progesterone acts as an oncogenic hormone in prostate cancer, and strategies to eliminate its oncogenic effects may benefit prostate cancer patients.
Insights
Prostate cancer progression is linked to progesterone, not just androgens. Inhibiting progesterone production may offer new therapeutic strategies for patients, as elevated levels indicate poor outcomes.
Area of Science:
- Endocrinology
- Oncology
- Metabolomics
Background:
- Prostate cancer growth is typically linked to androgens.
- The progression of prostate cancer after androgen deprivation suggests other contributing factors, termed oncometabolites.
- The role of progesterone in prostate cancer has not been fully elucidated.
Purpose of the Study:
- To investigate the potential oncogenic effects of progesterone in prostate cancer.
- To identify therapeutic strategies targeting progesterone production or action.
Main Methods:
- Mass-spectrometry-based screening of clinical specimens.
- Retrospective analysis of clinical data from prostate cancer patients.
- Investigated the effects of progesterone on androgen receptor (AR) target genes and cell proliferation via GATA2.
Main Results:
- Progesterone, at high doses, activates both canonical and non-canonical AR target genes.
- Physiological levels of progesterone promote cell proliferation through GATA2.
- Inhibitors of 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) were found to suppress progesterone generation.
- Increased progesterone levels correlate with poorer clinical outcomes and may serve as a predictive biomarker.
Conclusions:
- Progesterone acts as an oncogenic hormone in prostate cancer.
- Targeting progesterone generation or its effects presents a potential therapeutic avenue for prostate cancer patients.
- Progesterone may be a useful predictive biomarker for prostate cancer prognosis.
More Related Videos
Related Concept Videos
Inhibition of Cdk Activity
Abnormal Proliferation
Negative Regulator Molecules
Hedgehog Signaling Pathway

